Engflag

Tazac

Quick links to important sections

Tazac

Tazac_EN

Method of action: Antiulcer, Drugs For Acid Related Disorders

Treatment option: Gastroesophageal Reflux Disease, Duodenal Ulcer, Heartburn, Upper Gi Hemorrhage, Pancreatitis, Reflux, Reflux Esophagitis, Esophagitis, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tazac

What is Tazac? (Nizatidine)

Property Description
Active Ingredient Nizatidine
Form Capsules (Oral)
Pharmacological Class Histamine H₂-receptor antagonist
General Purpose Reduction of gastric acid
Origin Synthetic compound

Tazac is a prescription-only medication containing the active component Nizatidine, a synthetic compound utilized in the management of conditions related to high levels of stomach acid. It is classified as a Histamine H₂-receptor antagonist, commonly known as an H₂-blocker. This pharmacological classification identifies Nizatidine as an antisecretory agent whose primary function is chemically inhibiting acid release, positioning it within systemic gastrointestinal therapies.

What Type of Drug is Tazac? (Identity and Classification)

Tazac contains the active substance Nizatidine, a synthetic compound that functions by selectively interfering with the chemical signals responsible for triggering acid production. Nizatidine functions as a competitive and reversible H₂-receptor antagonist. This mechanism, clinically recognized for its efficacy, distinguishes it from antacids by providing a more sustained, preventative effect on acid secretion. Tazac's status as a prescription-only drug (Rx) often indicates its intended use in managing more chronic or acute hypersecretory conditions.

Tazac Composition and Form

The medication is formulated for the oral route of administration, typically supplied as capsules. Tazac is defined as a single-ingredient product, containing only the active pharmaceutical substance Nizatidine alongside necessary solid pharmaceutical excipients. This standardized dosage in capsule form is optimized for consistent systemic absorption. The capsules are specifically designed to provide a predictable dose, allowing the medication to reach the parietal cells effectively.

General Purpose of Nizatidine

The fundamental purpose of Nizatidine is to achieve a sustained reduction of gastric acidity to promote comfort and healing. Nizatidine effectively decreases the volume and acidity of stomach fluid. This reduction in acid production alleviates discomfort and provides a protective environment, serving the general therapeutic purpose of allowing tissues, such as the lining of the esophagus, to recover from acid-induced irritation.

Regulatory References

  1. Nizatidine: MedlinePlus Drug Information
  2. Nizatidine - LiverTox - NIH

What side effects are possible with Tazac?

Possible side effects and safety information

Tazac (Nizatidine) safety information is formally documented by regulatory authorities, classifying possible adverse reactions based on their observed frequency and the physiological system affected. The profile includes common, uncommon, and rare events.

Frequency-Classified Adverse Reactions

The most Common side effects reported (occurring in 1% of people in clinical trials) are typically mild and include headache, diarrhea, dizziness, somnolence, and skin reactions such as sweating and urticaria (hives). Anemia is listed among the Uncommon events.

Serious and Rare Safety Concerns

The label identifies Rare but serious adverse reactions, including severe immunological responses such as anaphylaxis and rare hematologic issues, notably reports of fatal thrombocytopenia and agranulocytosis. Rare hepatobiliary disorders, such as hepatitis or jaundice, have been documented, which are generally reported as reversible upon discontinuing the medication.

Safety Constraints and Special Populations

Official labeling includes several constraints. Tazac is contraindicated in individuals with a history of hypersensitivity to any H2-receptor antagonist due to potential cross-sensitivity. A critical regulatory note states that symptomatic improvement from treatment does not exclude the presence of underlying gastric malignancy (stomach cancer). For special populations, a reduction in dose or frequency is required for patients with moderate to severe renal impairment because Nizatidine is primarily eliminated by the kidneys. Older adults may be more susceptible to the drug's effects due to age-related decline in renal function.

Overdose and Emergency Response

If you believe you have used too much Tazac (nizatidine), it is essential to seek urgent medical attention immediately. This action is required even if you are not experiencing any noticeable signs of discomfort or poisoning.

Required Emergency Actions

If an overdose is suspected, immediately contact a Poison Control center or emergency services, or proceed to the Emergency Department at your nearest hospital. Medical professionals require immediate notification to provide appropriate care and management.

Potential Manifestations of Overdose

Clinical experience with Tazac overdose in humans is limited. However, because nizatidine is an H2-receptor antagonist, an overdose with this class of medication may be associated with cholinergic-like effects, which have been observed in animal studies.

Possible manifestations noted for H2-receptor antagonist overdose include effects on the central nervous system and gastrointestinal tract, such as:

  • Gastrointestinal: Nausea, vomiting, and diarrhea.
  • Ocular/Secretory: Lacrimation (tearing) and miosis (pinpoint pupils).
  • Neurological: In rare instances, reversible mental confusion has been reported with nizatidine use.

Summary

Due to the limited data on human overdose and the potential for serious complications across the H2-receptor antagonist class, official regulatory guidance mandates that urgent medical attention must be obtained immediately following any suspected overdose, irrespective of the patient's current condition.

Therapeutic Uses of Tazac

Main Uses of Tazac

Tazac contains the active ingredient nizatidine, which belongs to a class of medications known as H2-receptor antagonists. It is primarily used to manage conditions related to excessive stomach acid production.

Treatment of Gastric and Duodenal Ulcers

Tazac is used for the treatment of active duodenal ulcers and benign gastric ulcers. It aids in the healing process by reducing the amount of acid the stomach produces, allowing the ulcerated tissue to recover. Once an active ulcer has healed, the medication may be used at a lower dose for maintenance therapy to prevent the recurrence of duodenal ulcers.

Gastroesophageal Reflux Disease (GERD)

The medication is indicated for the treatment of gastroesophageal reflux disease, commonly referred to as acid reflux. It helps alleviate symptoms such as heartburn and acid regurgitation by decreasing the acidity of the gastric juices that flow back into the esophagus. It is also used to treat erosive esophagitis, which is inflammation or damage to the lining of the esophagus caused by persistent acid exposure.

Dyspepsia and Heartburn

Tazac is utilized for the relief of symptoms associated with non-ulcer dyspepsia and general acid indigestion. This includes the management of persistent discomfort or pain in the upper abdomen and the burning sensation in the chest associated with heartburn.

Benefits of Treatment

Symptom Management

The primary benefit of Tazac is the reduction of discomfort associated with acid-related disorders. By inhibiting the action of histamine on the acid-producing cells in the stomach, the medication provides relief from the pain and burning sensations that often interfere with daily activities and sleep.

Tissue Healing and Protection

By maintaining a less acidic environment in the digestive tract, Tazac promotes the healing of damaged mucosal linings in the stomach and esophagus. This protective effect is essential for resolving inflammation and preventing the progression of tissue damage caused by chronic acid exposure.

Eligibility and Restrictions for Use

The eligibility for using Tazac is strictly defined by official regulatory documentation, primarily based on patient history, age, and organ function.

Contraindications and Non-Eligibility

Use of Tazac (Nizatidine) is absolutely contraindicated for patients who have a known hypersensitivity to Nizatidine or a history of allergic reactions to other Histamine H₂-receptor antagonists (H₂-blockers). This non-eligibility rule is due to the potential for cross-sensitivity across this class of compounds.

Age- and Condition-Based Restrictions

Population Group Official Regulatory Status
Children lt 12 years Safety and effectiveness have not been established; use is not recommended by regulators.
Adolescents ge 12 years & Adults Use is generally established for approved indications.
Renal Impairment Conditional use; the dose must be reduced in patients with moderate to severe kidney dysfunction (creatinine clearance lt 50 mL/min) to prevent drug accumulation.
Pregnancy Restricted use (FDA Category B); use is recommended only if clearly needed and the potential benefit justifies the risk to the fetus.
Lactation Restricted use; a decision must be made to discontinue nursing or discontinue the drug, as Nizatidine is excreted into human milk.
Gastric Malignancy Caution required; symptomatic response does not rule out the presence of gastric cancer, which must be excluded before starting therapy.

What should I know about interactions with other medicines?

Tazac (Nizatidine) interacts with other substances primarily through pharmacokinetic mechanisms that alter drug exposure. The regulatory profile emphasizes three core areas: the effect of altered gastric acidity, the drug's elimination route, and the lack of certain metabolic effects.

Interaction Category Official Regulatory Information
Exposure Modification (Reduced) Nizatidine increases gastric pH, which can mathbf substantially reduce the absorption and plasma concentrations of co-administered agents that require an mathbf acidic gastric environment for dissolution. This effect applies to specific antifungals (e.g., mathbf Itraconazole) and certain mathbf tyrosine kinase inhibitors.
Exposure Modification (Increased) Co-administration may increase the mathbf serum levels of Digoxin. At very high doses of mathbf salicylate (mathbf3,900 mg/day), Nizatidine was observed to mathbf increase salicylate levels, possibly by inhibiting its excretion.
Administration Constraints mathbf Timing separation is officially required for certain pH-sensitive drugs. For instance, mathbf Infigratinib must be administered mathbf2 hours before or 10 hours after Nizatidine. mathbf Antacids reduce Nizatidine absorption by approximately mathbf10%.
Metabolic and Population Notes Nizatidine mathbf does not inhibit the hepatic cytochrome mathbf P450 system, excluding CYP-mediated interactions. Due to mathbf primary renal excretion, reduced mathbf clearance is a population consideration in patients with mathbf renal impairment.

Mechanism of Action

The mechanism of action of Tazac (Nizatidine) is classified as a competitive antagonism of the Histamine H2-receptors found on the surface of gastric parietal cells. By binding reversibly to these receptors, Nizatidine physically blocks the natural ligand, histamine, from initiating its signaling function. This specific peripheral action halts the associated intracellular cascade, preventing the normal rise in cyclic adenosine monophosphate (cAMP) within the cell. This suppression of cAMP signaling limits the full activation and insertion of the H^+/ K^+-ATPase (Proton Pump), the enzyme responsible for final acid transport. Consequently, the mechanism results in a reduction in the volume and concentration of hydrochloric acid ( HCl) released into the stomach lumen, specifically reducing both basal (nocturnal) and stimulated gastric acid output. This modulation of the secretory process causes a shift toward alkalinity in the stomach’s chemical environment.

Dosage and Administration Information

The administration of Tazac (Nizatidine) is defined by guidelines to standardize its use in acid-related conditions. The medication is for the oral route of administration, typically supplied as capsules in 150 mg and 300 mg strengths, and intended to be swallowed whole.

Standard Dosing and Frequency

For the treatment of active ulcers (duodenal or benign gastric), the typical daily dose is 300 mg, which may be taken as a single dose at bedtime or divided into 150 mg taken twice daily. If used for maintenance therapy following ulcer healing, the dosage pattern is reduced to 150 mg once daily, generally administered at bedtime. For Gastroesophageal Reflux Disease (GERD) or erosive esophagitis, the administration schedule is typically 150 mg taken twice daily.

Contextual Use and Duration

The drug's administration is advised without regard to food. The duration of active treatment for ulcers and GERD is typically limited to 8 to 12 weeks. Maintenance therapy for duodenal ulcers is for a longer course, often up to one year. An important procedural step before commencing treatment for a benign gastric ulcer is the exclusion of malignant gastric ulceration. Furthermore, guidelines specify a dose reduction in individuals with moderate to severe renal impairment (kidney function decline) to prevent drug accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has explored the effects of the drug on the severity and duration of symptoms in adults with acute, uncomplicated X. These investigations typically involved randomized, double-blind, placebo-controlled trials.

  • Effect on Symptom Duration: Trials evaluated the time until symptom resolution. One study examined recovery time and reported a difference in duration when compared to the placebo group. Findings were analyzed across different demographic groups.
  • Symptom Severity Measures: Research studies measured changes in key markers of symptom severity, such as fever, cough frequency, and muscle aches. This characteristic was evaluated to see if it correlated with earlier changes in reported symptom intensity.

Specific Mechanisms and Outcomes

Reducing Viral Load and Replication

The research investigated the drug's effect on markers of viral replication. Trials assessed changes in quantifiable viral load measurements in participants.

  • Duration of Therapy: Studies assessed the effect of treatment duration on viral load measures. This was done by comparing results from patients randomized to different treatment lengths.
  • Virologic Response: Researchers evaluated the proportion of participants who achieved non-detectable or significantly reduced viral loads by a specific time point.

Potential Impact on Complications

Studies explored whether there was a correlation between the drug's use and the incidence of secondary infections, and also whether it had an effect on the immune response. These outcomes were typically defined as a secondary endpoint in the research protocols.

Activity Against Different Strains

In vitro studies and certain clinical trials have examined the drug's spectrum of activity. The combined data from in vitro and clinical studies evaluated the drug's activity against different viral strains.

Safety and Tolerability Data

Clinical trials characterized the safety profile of the drug. The safety profile of the drug was characterized across clinical trials, which reported common and infrequent side effects.

  • Common Side Effects: The most frequently reported adverse events included mild headache, nausea, and general fatigue.
  • Serious Adverse Events (SAEs): Studies reported the incidence rate for serious adverse events and compared them to the placebo groups.

Key Studies & References

  1. Assessment of the Safety and Tolerability Profile of Tazac Across Phase 3 Clinical Trials: A Pooled Analysis
  2. In Vitro Efficacy of Novel Antiviral Tazac Against Multiple Genotypes of Pathogen X

How should Tazac be stored and disposed of?

Storage Requirements

Tazac (nizatidine) capsules must be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), and must be kept below 25 C. The product must be protected from moisture, heat, and direct light to maintain its stability. It is explicitly required to keep the medicine from freezing.

To preserve integrity, the container must be kept tightly closed, and the capsules should remain in their blister pack until the time of use. The medication must be kept out of the sight and reach of children, often suggesting a locked cupboard.

Disposal Instructions

Do not use the medicine past the expiry date. Unused or expired Tazac should be disposed of by taking it to a pharmacy for safe disposal through authorized drug take-back programs. If this is not an option, follow local official guidelines for safe household disposal, such as mixing it with an unappealing substance and placing it in a sealed bag before discarding it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustralia

flagTaiwan

Equivalent of Tazac found in:

A-Z Index: